KOSDAQBiotech & Pharma331920

Celemics

₩6,210▼ 10.13%2026-11-18 close
Market Cap
₩69.4B
Turnover
₩1.8B
Volume
320K
Shares out.
11.2M
PER
—
PBR
—
EPS
-₩1,567
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Losses persist; financing and new businesses are the swing factors

Celemics' revenue has been shrinking and operating losses have continued for five consecutive quarters, while its large capital raise and planned acquisitions of other companies' securities are the variables that could reshape its earnings path.

  1. 1

    Third-quarter 2026 revenue was KRW 854 million and the operating loss was KRW 1.85 billion, with revenue down and the loss wider than a year earlier.

  2. 2

    For 2025, the operating loss was KRW 3.32 billion and the net loss attributable to controlling shareholders was KRW 4.04 billion, so the 2024 swing to profit did not carry through.

  3. 3

    Through a rights-free capital raise and convertible bond issues in the first half of 2026, the company said it secured about KRW 31 billion in liquidity.

  4. 4

    About KRW 11.5 billion of the proceeds is earmarked for acquiring securities of other companies as a first step in new businesses.

  5. 5

    Private equity firm Soon & Financial Investment acquired the company's convertible bonds, and reports say an earn-out clause was set, raising the possibility of a management transfer after the 2027 shareholders' meeting.

02

Business structure

Celemics provides disease diagnostics and genomic analysis solutions based on next-generation sequencing (NGS).

The company says it is the only firm in Asia and Europe with NGS panel synthesis technology, and it is expanding into precision medicine and molecular diagnostics, including liquid biopsy and bio-drug development.

Reports differ on revenue mix: one report said about 65% comes from kits for detecting gene mutations in genetic diseases and solid tumors, with the rest from analysis services. A data aggregator, using Q2 2026 revenue, shows Target Capture kits at 85% and NGS services at 15%.

Because the two classifications differ, the segment split is better read as a range. Sales are reported to be weighted toward overseas markets, and the company said overseas revenue grew 40% in 2024 and exceeded one-third of total revenue.

Customers include domestic public institutions such as the National Cancer Center and the Korea Disease Control and Prevention Agency, plus global partners in the US, India, China and Europe. The company holds a 2025–2026 supply contract with KDCA for infectious disease whole-genome analysis.

Five products were reportedly listed as FDA Class 1 medical devices. Unlike pharma peers centered on therapeutic pipelines, Celemics' revenue rests on diagnostic kits and analysis services.

Alongside upgrading its core NGS technology, the company is pursuing acquisitions of other companies and entry into new businesses.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩1.3B-₩1.1B−85.4%
2025Q4₩1.7B-₩500M−27.5%
2026Q1₩900M-₩1.4B−154.4%
2026Q2₩1.4B-₩900M−67.2%
2026Q3₩900M-₩1.8B−216.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩8.7B-₩5.7B-₩4.8B−65.7%−25.8%19.5%
2023₩6.6B-₩5.8B-₩3.9B−87.7%−24.4%14.1%
2024₩6.7B-₩1.9B₩12.3B−28.3%45.1%8.2%
2025₩5.8B-₩3.3B-₩4B−57.6%−17.5%6.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

On a DART-filed annual basis, revenue fell from KRW 8.73 billion in 2022 to KRW 6.58 billion in 2023 (down 24.6% year on year), edged up to KRW 6.72 billion in 2024 (up 2.1%), and then dropped to KRW 5.77 billion in 2025 (down 14.2%). Among 2022–2025, 2022 was the largest year and 2025 the smallest.

The operating loss was KRW 5.73 billion in 2022, KRW 5.77 billion in 2023 (losses widened), KRW 1.9 billion in 2024 (losses narrowed) and KRW 3.32 billion in 2025 (losses widened), marking four consecutive years of losses from 2022 to 2025.

The operating margin was -65.7% in 2022, -87.7% in 2023, -28.3% in 2024 and -57.6% in 2025, so 2024 had the smallest loss margin.

Net income attributable to controlling shareholders moved from a net loss of KRW 4.8 billion in 2022 and KRW 3.88 billion in 2023 to a profit of KRW 12.3 billion in 2024, then back to a net loss of KRW 4.04 billion in 2025.

The 2024 swing to profit was far larger than the operating loss, which points to a large non-operating contribution. The company attributed the 2024 improvement to cost reduction, organizational efficiency and the exit from low-margin product sales such as peripherals and disposable reagents.

In 2025, the company said a deterioration in profitability widened the operating loss and that a fair-value loss on financial assets, tied to a fall in the value of equity investments in other companies, was recognized.

The debt ratio fell from 19.5% in 2022 to 6.0% in 2025, with total equity of KRW 23 billion and total liabilities of KRW 1.39 billion at end-2025. Operating cash flow was negative KRW 4.15 billion in 2022, negative KRW 4.53 billion in 2023, negative KRW 380 million in 2024 and negative KRW 3.6 billion in 2025.

Quarterly revenue went from KRW 1.66 billion in Q4 2025 (up 31.5% quarter on quarter) to KRW 923 million in Q1 2026 (down 44.3%), KRW 1.38 billion in Q2 2026 (up 49.0%) and KRW 854 million in Q3 2026 (down 37.9%).

The operating loss was KRW 1.08 billion in Q3 2025, KRW 456 million in Q4 2025, KRW 1.43 billion in Q1 2026, KRW 924 million in Q2 2026 and KRW 1.85 billion in Q3 2026. Operating losses have been reported in each of the last five quarters, from Q3 2025 through Q3 2026.

One analysis links the decline in key product sales in Q1 2026, including Target Capture Kit and BTSeq Kit, to lower gross profit and operating profit.

The net loss attributable to controlling shareholders was KRW 814 million in Q4 2025, KRW 6.05 billion in Q1 2026, KRW 5.23 billion in Q2 2026 and KRW 2.99 billion in Q3 2026, totaling KRW 15.1 billion over the last four quarters.

The Q1 2026 net loss was far larger than that quarter's operating loss of KRW 1.43 billion, suggesting non-operating items weighed heavily.

05

Industry analysis

Celemics' demand base spans precision medicine, liquid biopsy and infectious disease genomics. Expectations of rising demand from the industrialization of precision medicine and the expansion of liquid-biopsy cancer early detection are noted, but a near-term earnings recovery is seen as the main challenge.

In the cycle, the company expanded in earnest during the COVID-19 pandemic, and reports say its revenue has not grown over the past five years, suggesting it is rebuilding its demand base after the pandemic surge.

Infectious disease events are also a variable: after a hantavirus infection case on a cruise ship, the company drew attention for its NGS panel technology capable of hantavirus analysis. Public demand is partly supported by its supply contract with KDCA.

Within the sector, unlike large manufacturers such as Samsung Biologics and Celltrion or platform companies such as Alteogen, Celemics is small in both market capitalization and revenue, with sales concentrated in diagnostic kits and services.

Its technology claims rest largely on company statements and should be read alongside independent market-share data. A high overseas revenue share exposes it to currency swings and changing regulations in each country. The key industry test is whether core kit sales recover on a quarterly basis in the next periodic reports.

06

Outlook

The company said it will use the secured funds to upgrade its core NGS technology and maximize profitability.

On new businesses, about KRW 11.5 billion of the roughly KRW 31 billion raised has been earmarked for acquiring securities of other companies, and the company said it is following legitimate and transparent procedures. In a shareholder letter, the CEO pledged to disclose the details and roadmap for the new businesses.

For the core business, the company plans to strengthen strategic collaboration with domestic and global large companies to commercialize technology and expand global sales.

Financing structure is also part of the outlook: a convertible bond announced on March 31, 2026 raises KRW 27 billion for operating funds and matures on April 28, 2029. The KRW 5 billion bond issued in February 2026 can be converted from February 27, 2027 to January 27, 2029.

On governance, Soon & Financial Investment is acquiring the company's convertible bonds, reportedly under an earn-out clause, and a scenario has been raised in which it takes over management after the shareholders' meeting in 2027.

The next checkpoints are the scale of the full-year operating loss and whether fourth-quarter revenue recovers in the 2026 annual report, along with disclosures on the new-business acquisitions and whether the roadmap is published.

07

Valuation

PER
—
PBR
—
ROE
-58.8%
EPS
-₩1,567
BPS
—
Dividend per share
₩0

Because the net loss attributable to controlling shareholders totaled KRW 15.1 billion over the last four quarters, the price-to-earnings ratio cannot be calculated on an earnings basis. Market capitalization is above total equity at end-2025, so the premium to book value is large.

Dividends are effectively negligible, so the dividend yield is below the sector average. Where earnings-based metrics do not apply, equity size and financing capacity become the central references for interpreting the share price.

The company swung to profit in 2024 but returned to a loss in 2025, so earnings have not built up steadily. Dilution also matters: the KRW 5 billion convertible bond issued in February 2026 would represent 20.6% of total shares on conversion, and the KRW 27 billion bond issued in March 2026 would represent 25.43%.

Because the earn-out structure pays the acquisition price in installments tied to performance, capital inflows from that channel are harder to sustain without an earnings improvement.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

NGS technology and certification base

The company says it is the only firm in Asia and Europe with NGS panel synthesis technology. Reports say five products are listed as FDA Class 1 medical devices, and a KDCA supply contract forms an existing public demand base. Expansion of the liquid-biopsy market is a medium- to long-term pillar of product demand.

Financing capacity and low debt

The company said it secured about KRW 31 billion in cash liquidity including recent convertible bond issuance. On the DART-filed basis, the debt ratio fell from 19.5% in 2022 to 6.0% in 2025, so financial burden is small. Financial room to fund both core upgrades and new businesses is cited as a strength.

Signs of cost structure improvement

The operating loss fell to KRW 1.9 billion in 2024 from KRW 5.77 billion in 2023. The company credited cost reduction, organizational efficiency and the exit from low-margin products.

The narrower Q2 2026 operating loss of KRW 924 million, compared with KRW 1.43 billion in Q1, can also be read as an early sign of recovery.

09

Bear factors

Shrinking revenue and continued losses

Revenue fell from KRW 8.73 billion in 2022 to KRW 5.77 billion in 2025, and operating losses ran for four consecutive years from 2022 to 2025. Q3 2026 revenue of KRW 854 million was down 32.3% from a year earlier.

The Q3 2026 operating loss of KRW 1.85 billion widened from the prior year, extending losses across the last five quarters.

Volatility in core product sales

One analysis links lower sales of key products, including Target Capture Kit and BTSeq Kit, to a sharp drop in gross profit and operating profit.

Quarterly revenue swung from KRW 1.66 billion in Q4 2025 to KRW 923 million in Q1 2026, KRW 1.38 billion in Q2 and KRW 854 million in Q3, making near-term earnings harder to predict.

Dilution and reliance on external funding

Rights offerings and convertible bonds followed one another in 2026. The February 2026 KRW 5 billion CB equals 20.6% of total shares on conversion, and the March 2026 KRW 27 billion CB equals 25.43%. If operating losses continue and funding needs recur, cumulative shareholder dilution could rise.

10

Risk factors

Dilution and convertible supply

The conversion request period for the February 2026 CB begins February 27, 2027. Combined with the March 2026 CB, the number of shares that could be issued on conversion is large. Share count growth at conversion could weigh on value per share, so both the timing and size of conversion supply need monitoring.

New-business execution and investment valuation

About KRW 11.5 billion of the roughly KRW 31 billion raised is earmarked for acquiring other companies' securities, but the specifics of the new businesses and their link to the core business are hard to judge before the roadmap is disclosed.

In 2025, a fair-value loss on investments in other companies hit earnings, so valuation swings in investment assets can move profit.

Governance change and shareholder shifts

Soon & Financial Investment invested KRW 8.55 billion as a strategic investor on April 28, 2026. In March 2026, one shareholder sold its entire stake on the open market, and two outside directors were newly appointed to the board.

If a management-transfer scenario materializes, business direction and funding policy could change, so shareholder composition needs ongoing monitoring.

11

What to watch next

  1. From February 27, 2027

    This is when conversion requests for the February 2026 CB can begin. The conversion represents 20.6% of total shares, so dilution scale is the key point to track.

  2. Late March 2027 (annual report filing deadline)

    The 2026 annual report is due. The next checkpoint is the fourth-quarter revenue and full-year operating loss in the DART filing, compared with 2025 revenue of KRW 5.77 billion and an operating loss of KRW 3.32 billion.

  3. Around May 15, 2027 (Q1 quarterly report deadline)

    The Q1 2027 quarterly report is due. The comparison base is the Q1 2026 operating loss of KRW 1.43 billion and net loss attributable to controlling shareholders of KRW 6.05 billion, looking at non-operating items and whether core kit sales recover.

  4. Around the 2027 annual general meeting

    This is where to check whether the management-transfer scenario tied to the earn-out terms materializes, along with board composition and changes in the largest shareholder.

  5. Ad hoc disclosures (timing not fixed)

    Watch for disclosures on the roughly KRW 11.5 billion used to acquire other companies' securities and whether the new-business roadmap promised in the shareholder letter is published.

12

Overall view

Celemics is a biotech company centered on NGS-based diagnostic kits and analysis services. On a DART-filed basis, revenue fell from KRW 8.73 billion in 2022 to KRW 5.77 billion in 2025, and the company posted operating losses for four consecutive years from 2022 to 2025.

The Q3 2026 operating loss of KRW 1.85 billion widened the loss, and losses have continued for the last five quarters. Positives include FDA Class 1-listed products, a KDCA supply contract, a debt ratio of 6.0%, and about KRW 31 billion of funds secured in the first half of 2026.

On the other side, core kit sales swing sharply by quarter, and convertible bond conversions carry dilution equal to 20.6% and 25.43% of total shares. About KRW 11.5 billion has been earmarked for acquiring other companies' securities, but the specifics have not yet been disclosed.

The earn-out structure and management-transfer scenario tied to Soon & Financial Investment are also governance variables.

The next checkpoints are the full-year operating loss and Q4 revenue in the 2026 annual report, convertible conversion supply from February 27, 2027, and whether core sales recover in the Q1 2027 quarterly report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.fnguide.com
  2. pharmnews.com
  3. news.bbsi.co.kr
  4. news.nate.com
  5. vegannews.co.kr
  6. news.nate.com
  7. sedaily.com
  8. butler.works
  9. v.daum.net
  10. tlo.korea.ac.kr
  11. news.nate.com
  12. digitaltoday.co.kr
  13. news.nate.com
  14. m.news.nate.com
  15. news.nate.com
  16. digitaltoday.co.kr
  17. m.news.nate.com
  18. finance.eduinfom.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis